Severe Guillain-Barre syndrome induced by intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report.

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL
AME Case Reports Pub Date : 2024-08-19 eCollection Date: 2024-01-01 DOI:10.21037/acr-23-107
Feng Zhou, Xiaoha Lin, Junfei Zhong, Lingjuan Zhu, Jinfeng Deng, Zhengtao Zheng
{"title":"Severe Guillain-Barre syndrome induced by intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report.","authors":"Feng Zhou, Xiaoha Lin, Junfei Zhong, Lingjuan Zhu, Jinfeng Deng, Zhengtao Zheng","doi":"10.21037/acr-23-107","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Guillain-Barré syndrome (GBS) is an acute/subacute immune-mediated polyneuropathy characterized by varying degrees of limb or cranial nerve involvement, manifested as limb weakness, absent tendon reflexes, and sensory and autonomic dysfunction caused by demyelination and/or axonal damage of peripheral nerves and nerve roots. Upper respiratory tract infections and gastroenteritis are the most important triggering factors, but the occurrence of explosive GBS after injection of ranibizumab is very rare.</p><p><strong>Case description: </strong>A 53-year-old female was diagnosed with left branch retinal vein occlusion (RVO) and underwent three intravitreal injections of ranibizumab (0.5 mg) in the left eye. After the third injection, she developed weakness, numbness, and tingling in the limbs, which worsened to respiratory muscle paralysis requiring mechanical ventilation and tracheostomy. Cerebrospinal fluid showed protein-cell dissociation, a positive anti-ganglioside antibody spectrum, and electromyography revealed multiple demyelinating changes in peripheral nerves. The diagnosis was GBS. After treatment with immunoglobulin (25 g) therapy, the patient improved. After two months of treatment, the tracheotomy site healed well, and the patient was able to walk independently and perform basic activities of daily living. After one year of follow-up, the patient did not experience a relapse and was basically cured. This successful outcome highlights the importance of promptly recognizing and treating GBS induced by ranibizumab, which is crucial for optimizing patient outcomes and preventing potential life-threatening consequences in patients with RVO.</p><p><strong>Conclusions: </strong>This case underscores the potential occurrence of GBS in patients undergoing ranibizumab treatment for RVO. It highlights the importance for clinicians to promptly recognize and diagnose GBS, initiate appropriate interventions, optimize patient outcomes, and prevent potential life-threatening consequences.</p>","PeriodicalId":29752,"journal":{"name":"AME Case Reports","volume":"8 ","pages":"96"},"PeriodicalIF":0.7000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459426/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AME Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/acr-23-107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Guillain-Barré syndrome (GBS) is an acute/subacute immune-mediated polyneuropathy characterized by varying degrees of limb or cranial nerve involvement, manifested as limb weakness, absent tendon reflexes, and sensory and autonomic dysfunction caused by demyelination and/or axonal damage of peripheral nerves and nerve roots. Upper respiratory tract infections and gastroenteritis are the most important triggering factors, but the occurrence of explosive GBS after injection of ranibizumab is very rare.

Case description: A 53-year-old female was diagnosed with left branch retinal vein occlusion (RVO) and underwent three intravitreal injections of ranibizumab (0.5 mg) in the left eye. After the third injection, she developed weakness, numbness, and tingling in the limbs, which worsened to respiratory muscle paralysis requiring mechanical ventilation and tracheostomy. Cerebrospinal fluid showed protein-cell dissociation, a positive anti-ganglioside antibody spectrum, and electromyography revealed multiple demyelinating changes in peripheral nerves. The diagnosis was GBS. After treatment with immunoglobulin (25 g) therapy, the patient improved. After two months of treatment, the tracheotomy site healed well, and the patient was able to walk independently and perform basic activities of daily living. After one year of follow-up, the patient did not experience a relapse and was basically cured. This successful outcome highlights the importance of promptly recognizing and treating GBS induced by ranibizumab, which is crucial for optimizing patient outcomes and preventing potential life-threatening consequences in patients with RVO.

Conclusions: This case underscores the potential occurrence of GBS in patients undergoing ranibizumab treatment for RVO. It highlights the importance for clinicians to promptly recognize and diagnose GBS, initiate appropriate interventions, optimize patient outcomes, and prevent potential life-threatening consequences.

玻璃体内注射雷尼珠单抗治疗视网膜分支静脉闭塞诱发严重格林巴利综合征:病例报告。
背景:吉兰-巴雷综合征(GBS吉兰-巴雷综合征(Guillain-Barré syndrome,GBS)是一种急性/亚急性免疫介导的多发性神经病,以不同程度的肢体或颅神经受累为特征,表现为肢体无力、腱反射消失,以及由周围神经和神经根脱髓鞘和/或轴索损伤引起的感觉和自主神经功能障碍。上呼吸道感染和胃肠炎是最重要的诱发因素,但注射雷尼珠单抗后发生爆发性 GBS 的情况非常罕见:一名 53 岁的女性被诊断为左侧视网膜分支静脉闭塞(RVO),并在左眼接受了三次雷尼珠单抗(0.5 毫克)玻璃体内注射。第三次注射后,她出现四肢无力、麻木和刺痛,并恶化为呼吸肌麻痹,需要进行机械通气和气管造口术。脑脊液显示蛋白-细胞分离,抗神经节苷脂抗体谱阳性,肌电图显示周围神经多发性脱髓鞘病变。诊断结果为 GBS。在接受免疫球蛋白(25 克)治疗后,患者病情有所好转。治疗两个月后,气管切开部位愈合良好,患者能够独立行走并进行基本的日常生活活动。经过一年的随访,患者未再复发,基本痊愈。这一成功的结果凸显了及时识别和治疗雷尼珠单抗诱发的GBS的重要性,这对于优化患者预后和防止RVO患者出现潜在的危及生命的后果至关重要:本病例强调了接受雷尼珠单抗治疗的 RVO 患者可能发生 GBS。结论:本病例强调了在接受雷尼珠单抗治疗的 RVO 患者中可能发生 GBS,并突出了临床医生及时识别和诊断 GBS、采取适当干预措施、优化患者预后以及预防潜在的危及生命后果的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信